• 1
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 2
    Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 3
    Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 699701.
  • 4
    Samuel D, Weber R, Stock P, Duclos Vallée JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008; 48: 697707.
  • 5
    Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 2004; 364: 8394.
  • 6
    González-García JJ, Mahillo B, Hernández S, Pacheco R, Diz S, García P, et al. Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm Infecc Microbiol Clin 2005; 23: 340348.
  • 7
    Miró JM, Torre-Cisneros J, Moreno A, Tuset M, Querada C, Laguno M, et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain—March, 2005. Enferm Infecc Microbiol Clin 2005; 23: 353362.
  • 8
    Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 14251430.
  • 9
    Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779789.
  • 10
    Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 4957.
  • 11
    Fink SA, Brown RS. Current indication, contraindications, delisting criteria, and timing for liver transplantation. In: BusuttilRW, KlintmalmGK, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005: 95114.
  • 12
    Cardenas A, Gines P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005; 42: S124S133.
  • 13
    Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823830.
  • 14
    Sola R, Alvarez MA, Balleste B, Montoliu S, Rivera M, Miquel M, et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int 2006; 26: 6272.
  • 15
    Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 2002; 34: 569572.
  • 16
    Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 17
    Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 18
    Girón-González JA, Brun F, Terrón A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antivir Ther 2007; 12: 899907.
  • 19
    Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, et al. MELD is the best predictor of pre-transplant mortality in HIV-infected liver transplant candidates. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 64.
  • 20
    Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for End Stage Liver Disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897903.
  • 21
    Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB, McDiarmid SV, Merion RM, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. Liver Transpl 2004; 10(suppl 2): A6A22.
  • 22
    Maida I, Nunez M, Gonzalez-Lahoz J, Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation? AIDS Res Hum Retroviruses 2005; 21: 599601.
  • 23
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307313.